The Era of an 80% Generic Drug Volume Share
First written in FY2016-Q3. 9 of 10 entries say "Restated". Latest entry: FY2019-Q3.
2 other companies' latest entry also says "Restated".
- FY2019-Q3RestatedAnnual report
「The volume of generic pharmaceuticals supplied is expected to increase further as an important measure to contain national healthcare spending. At the same time, measures to ensure stable supply and further drug price reductions are anticipated.」
Expected growth in the volume of generic pharmaceuticals supplied, and the need to address stable supply and drug price reductions, continue to be described. - FY2019-Q2RestatedAnnual report
「The volume of generic pharmaceuticals supplied is expected to increase further as an important measure to contain national healthcare spending. At the same time, measures to ensure stable supply and further drug price reductions are anticipated.」
Expected growth in the volume of generic pharmaceuticals supplied, and the need to address stable supply and drug price reductions, continue to be described. - FY2019-Q1RestatedAnnual report
「The volume of generic pharmaceuticals supplied is expected to increase further as an important measure to contain national healthcare spending. At the same time, measures to ensure stable supply and further drug price reductions are anticipated.」
Expected growth in the volume of generic pharmaceuticals supplied is described as part of the business environment, with continued recognition of the need to address stable supply and drug price reductions. - FY2018-Q3RestatedAnnual report
「The volume of generic pharmaceuticals supplied is expected to increase further as an important measure to contain national healthcare spending. At the same time, measures to ensure stable supply and further drug price reductions are anticipated.」
Expected growth in the volume of generic pharmaceuticals supplied is described as part of the business environment, with continued recognition of the need to address stable supply and drug price reductions. - FY2018-Q2RestatedAnnual report
「The volume of generic pharmaceuticals supplied is expected to increase further as an important measure to contain national healthcare spending. At the same time, measures to ensure stable supply and further drug price reductions are anticipated.」
Expected growth in the volume of generic pharmaceuticals supplied is described as part of the business environment, with continued recognition of the need to address stable supply and drug price reductions. - FY2017RestatedAnnual report
「The Ministry of Health, Labour and Welfare announced the Comprehensive Strategy to Strengthen the Pharmaceutical Industry, a comprehensive strategy to strengthen the industry's competitiveness in order to achieve, as part of the transition to an era of 80% generic drug use, the stable supply of high-quality pharmaceuticals to the public, more efficient healthcare spending and stronger industrial competitiveness as an integrated set of objectives.」
The era of 80% generic drug use continues to be described as part of the business environment. - FY2017-Q3RestatedAnnual report
「The Ministry of Health, Labour and Welfare announced the Comprehensive Strategy to Strengthen the Pharmaceutical Industry, a comprehensive strategy to strengthen the industry's competitiveness in order to achieve, as part of the transition to an era of 80% generic drug use, the stable supply of high-quality pharmaceuticals to the public, more efficient healthcare spending and stronger industrial competitiveness as an integrated set of objectives.」
Recognition of the business environment as an era of 80% generic drug use continues to be described. - FY2017-Q2RestatedAnnual report
「The Ministry of Health, Labour and Welfare announced the Comprehensive Strategy to Strengthen the Pharmaceutical Industry, a comprehensive strategy to strengthen the industry's competitiveness in order to achieve, as part of the transition to an era of 80% generic drug use, the stable supply of high-quality pharmaceuticals to the public, more efficient healthcare spending and stronger industrial competitiveness as an integrated set of objectives.」
Recognition of the business environment as an era of 80% generic drug use continues to be described. - FY2017-Q1RestatedAnnual report
「The Ministry of Health, Labour and Welfare announced the Comprehensive Strategy to Strengthen the Pharmaceutical Industry, a comprehensive strategy to strengthen the industry's competitiveness in order to achieve, as part of the transition to an era of 80% generic drug use, the stable supply of high-quality pharmaceuticals to the public, more efficient healthcare spending and stronger industrial competitiveness as an integrated set of objectives.」
Recognition of the business environment as an era of 80% generic drug use continues to be described. - FY2016-Q3First statedAnnual report
「At least 70% by mid-2017, and at least 80% as early as possible between FY2018 and the end of FY2020」
The government's target for generic drug volume share is described as part of the business environment.